Aripiprazole: A new atypical antipsychotic with a different pharmacological mechanism

  • Naber D
  • Lambert M
  • 37


    Mendeley users who have this article in their library.
  • 56


    Citations of this article.


Aripiprazole is a new atypical antipsychotic with a mode of action that is distinct from currently available antipsychotic drugs. In phase III comparative clinical studies, aripiprazole 15-30 mg/day was at least as effective as haloperidol and risperidone in short term treatment of acute exacerbation of schizophrenia but superior to haloperidol in long term maintenance therapy. Consistent with an atypical profile, aripiprazole is effective against positive, negative and cognitive symptoms of schizophrenia and has a favourable side effect profile with the incidence of extrapyramidal symptoms (EPS) comparable to placebo. It is also devoid of side effects such as clinically significant hyperprolactinaemia, hypercholesterolaemia and cardiotoxicity, and has a low propensity for weight gain. Symptom relief is achieved without significant sedation. These clinical data suggest its usefulness in psychosocial rehabilitation, as well as in long-term prevention of schizophrenic relapse. Recent results from a multicentre, open-label study in a general psychiatric setting provide the first evidence that aripiprazole is also effective under naturalistic conditions. However, only post-marketing experience will show whether the positive results of these controlled trials can be replicated in everyday practice. © 2004 Elsevier Inc. All rights reserved.

Author-supplied keywords

  • Aripiprazole
  • Atypical antipsychotics
  • Schizophrenia

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Dieter Naber

  • Martin Lambert

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free